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Abstract
Background: Gestational age is often used as a proxy for developmental maturity by clinicians and researchers
alike. DNA methylation has previously been shown to be associated with age and has been used to accurately
estimate chronological age in children and adults. In the current study, we examine whether DNA methylation in
cord blood can be used to estimate gestational age at birth.
Results: We find that gestational age can be accurately estimated from DNA methylation of neonatal cord blood
and blood spot samples. We calculate a DNA methylation gestational age using 148 CpG sites selected through
elastic net regression in six training datasets. We evaluate predictive accuracy in nine testing datasets and find that
the accuracy of the DNA methylation gestational age is consistent with that of gestational age estimates based on
established methods, such as ultrasound. We also find that an increased DNA methylation gestational age relative
to clinical gestational age is associated with birthweight independent of gestational age, sex, and ancestry.
Conclusions: DNA methylation can be used to accurately estimate gestational age at or near birth and may provide
additional information relevant to developmental stage. Further studies of this predictor are warranted to determine its
utility in clinical settings and for research purposes. When clinical estimates are available this measure may increase
accuracy in the testing of hypotheses related to developmental age and other early life circumstances.
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Background
Differences in gestational age (GA) as small as one week
have been shown to have significant impacts on neonatal
morbidity and mortality, as well as long-term out-
comes [1–6]. In light of this, the American College of
Obstetricians and Gynecologists (ACOG) recently rec-
ommended revising the categorization of births from term
(>37 weeks gestation) and preterm (≤37 weeks gestation)
into several subcategories (early preterm, preterm, early
term, full term, late term, and post term) that better reflect
the developmental differences associated with GA at each
of these time points [7, 8]. Accurate classification systems
that reflect both developmental time and maturity may
improve our ability to predict neonatal risk.
Traditionally, GA is estimated using one or more of
the following methods: early obstetric ultrasound, last
menstrual period (LMP), or neonatal estimation [9].
Ultrasound-based methods are considered to be the gold
standard and have proven to be a better predictor of
delivery date [10] as LMP estimates may be influenced by
uncertainty regarding LMP dates, normal variations in ovu-
lation timing, atypical bleeding, and contraceptive use [9].
Neonatal estimation, which is based on a combination of
physical appearance, muscular tone, flexibility, and reflexes,
is the only available method for determining GA after birth
but is less precise than LMP and ultrasound [9, 11, 12].
In circumstances where LMP date is uncertain and
ultrasounds are not available, a more accurate method
for estimating GA may be beneficial.
Recently, DNA methylation (DNAm) has been used to
accurately predict chronological age in children and adults
[13–16]. Later work revealed that a methylation-based
prediction of age may also associate with physiological
consequences in adults when a study reported that an in-
creased methylation age relative to chronological age was
associated with an increase in mortality risk [17–22].
However, the predictors optimized in these studies were
not designed to estimate GA and did not attempt to differ-
entiate between different GA, as samples taken at birth
were either assigned an age of zero or were excluded from
the model [13, 14]. Because the accuracy and precision of
a prediction model is, in general, weakest at the extremes
of the distribution, a predictor developed from primarily
adult samples would, by nature, be less accurate in neo-
nates than one that is optimized for that purpose.
DNAm differences in specific CpG sites have been as-
sociated with GA at birth in multiple studies [23–26].
We hypothesize that a predictor designed specifically for
use with umbilical cord blood or blood spots already
routinely collected for newborn screening could allow
for accurate neonatal estimation of GA that may also be
informative of developmental stage. The objective of this
study was to develop such a predictor to estimate GA
from DNAm data using umbilical cord blood or blood
spot samples and to assess its ability to predict other
indicators of developmental maturity.
Results and Discussion
DNAm data from 1434 neonates, representing 15 inde-
pendent cohorts, were used for this study. For each sam-
ple, HumanMethylation27 or HumanMethylation450
BeadChips (Table 1; Additional file 1: Table S1) were
used to generate data from DNA extracted from umbil-
ical cord blood or blood spots. Of the 16,676 CpG sites
that passed quality control in the testing and training
datasets referenced in Table 1, 3155 (19 %) were at least
Table 1 Description of cohorts
Dataset N GA range (weeks) GA mean ± SD Male (%) Race Nationality Source Array
Training datasets
GSE36642 51 32–38 36.3 ± 1.7 56.9 White Australian Cord 27 k
WMHP1 40 31–41 37.9 ± 2.3 47.5 98 % white American Cord 450 k
GSE62924 38 34–41 39.1 ± 1.4 42.1 White Mexican Cord 450 k
NBC 36 24–41 36.0 ± 5.4 47.2 Black American Cord 450 k
GSE51180 23 25–42 32.7 ± 6.6 69.6 White Australian Spot 450 k
GSE30870 19 34–41 38.9 ± 2.1 NA White Spanish Cord 450 k
Test datasets
DNSBtrios 264 28–44 40.3 ± 1.9 64.9 White Danish Spot 450 k
WMHP2 251 33–43 38.7 ± 1.4 51.0 80 % white American Cord 27 k
CANDLE 198 32–41 39 ± 1.3 52.0 51 % black, 40.4 % white American Cord 27 k
VICS 183 24–35 28.0 ± 2.1 42.1 89 % white Australian Spot 450 k
PROGRESS 148 30–43 38.6 ± 1.7 52.0 White Mexican Cord 450 k
PREDO 91 31–42 39.6 ± 1.5 54.9 White Finnish Cord 450 k
Training datasets and test datasets were chosen to represent a similar range of gestational ages
NA not available, SD standard deviation
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nominally associated with GA in an epigenome-wide as-
sociation study (p < .05; Additional file 1: Figure S1), and
adjustment for proportions of white blood cell subtypes
and nucleated red blood cells had little effect on the
results (Additional file 1: Figure S2). Associated CpGs
were enriched for a range of biological processes, includ-
ing cell proliferation and chordate embryonic develop-
ment (Additional file 1: Table S2).
Predicting DNAm GA in neonates
To train the DNAm GA predictor, six independent cohorts
were selected to sample a wide range of GAs and ances-
tries. Consistent with the approach described by Horvath
[13], elastic net regression was used to select a set of 148
CpG sites (Additional file 2) predictive of GA from a set of
16,838 CpG sites that were available in all training datasets.
Although some of the individual studies report associations
between the perinatal environment and DNAm, no CpG
site reported to associate with environmental exposures in
these cohorts were among the sites selected for this pre-
dictor [27–30]. Overall, 90 out of 148 CpG sites selected
for the predictor (61 %) showed some evidence for associ-
ation with GA in the cell type-adjusted epigenome-wide
association study (p < 0.05). In the training datasets, correl-
ation between the resulting predictor (DNAm GA) and
clinically estimated GA was 0.99 (Fig. 1a), indicating a
strong fit of the model. The 148 CpG sites selected by the
elastic net were uniformly distributed across the genome
and were not located in genes more likely to be represented
among specific biological pathways (data not shown). They
were more likely to reside in CpG island shores than the
remaining 16,690 CpG sites that were eligible for inclusion
in the predictor (odds ratio (OR) = 1.73; p = 0.00096) and
less likely to reside in CpG islands (OR = 0.53; p = 0.00019)
or active promoters (OR = 0.59; p = 0.0028). The 148 sites
showed no significant enrichment or depletion for CpG is-
land shelves or enhancers (Additional file 1: Table S3). They
were also not enriched or depleted for sites with genetic
variants located in the probe sequence or sites previously
reported to associate with African American or Cauca-
sian race (Additional file 1: Table S3) [31–33].
The predictive accuracy of the model was tested in 1135
samples from six independent datasets. The testing and
training datasets had comparable GA distributions (Add-
itional file 1: Figure S3). In the testing datasets, overall cor-
relation between DNAm GA and GA was 0.91 (p < 2.20 ×
10−16; Fig. 1b). Within individual test datasets, correlation
between GA and DNAm GA remained high (0.52 < r <
0.65; Additional file 1: Figure S4) though appeared lower
than in the combined dataset due to lower sample sizes
and GA range. We were not able to obtain similar predict-
ive power using the DNAm age predictor proposed by
Horvath, which has a highly significant but much weaker
correlation with GA (r = 0.14, p = 4.89 × 10−6; Additional
file 1: Figure S5). This correlation coefficient is similar to
that observed for prenatal brain samples (r = 0.15) [34].
We did not evaluate the Hannum predictor [14] since it
is less accurate than the Horvath predictor in children [14,
35]. Of note, only six CpG sites included in the DNAm GA
predictor overlap with CpG sites in the predictor designed
by Horvath and no sites overlap with the predictor de-
signed by Hannum. However, one would not necessarily ex-
pect overlap. Elastic net regression selects a parsimonious
set of the full list of CpG sites and among highly correlated
CpG sites only one may be chosen, introducing an element
of chance into CpG selection. Moreover, the late gestational
period is associated with unique developmental changes
a
b
Fig. 1 Correlation between DNAm GA and GA. a DNAm GA and
estimated clinical GA (EGA) are highly correlated in the training dataset:
r = 0.99, median error (m.e.) = 0.35. b DNAm GA and estimated clinical
GA were also highly correlated in the testing dataset: r = 0.91, median
error = 1.24. Solid line = regression line; dotted line indicates equivalence
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that cannot be discriminated by the adult predictor, which
did not include measures of GA in its training dataset.
Thus, this lack of overlap may indicate that the CpG sites
predictive of GA in neonates are distinct from CpG sites
predicting age in adults because of their association with
changes specific to gestational development.
The average absolute difference between DNAm GA
and GA in test samples was 1.49 weeks, with a standard
deviation of 1.16 weeks. The median absolute difference
(“median error”) between DNAm GA and GA was
1.24 weeks. This falls well within the range of error for
clinical estimates of GA based on either LMP or ultra-
sound, as each of these clinical measures has an inherent
variability due to recall bias and natural phenotypic vari-
ation associated with development [9, 10, 36]. However, it
was interesting to note that DNAm GA correlated more
strongly with clinical GA estimates based on ultrasound
than those based exclusively on LMP (Additional file 1:
Figure S6). Error rates for ultrasound range from 5–7 days
if performed during the first trimester to 3.0–4.3 weeks
when performed in the third trimester. This predictor is
closer to clinical estimates of GA than post-birth measures
using neonatal estimation, which can overestimate the GA
of preterm neonates by up to 2.57 weeks [37–41].
The accuracy of this predictor is consistent with that
of established clinical methods for estimating GA,
though its accuracy can only be interpreted in the con-
text of the available clinical measurements. Predictive
accuracy was not influenced by neonatal sex as there
was no difference between the median errors in males
versus females (p = 0.76). The median error between
DNAm GA and clinically estimated GA was 1.07 for the
cord blood datasets and 1.57 for blood spot datasets.
This discrepancy may be due to differences in the preci-
sion of GA, as sample collection for blood spots was
performed up to 39 days after birth (Additional file 1:
Figures S3 and S7). It is also possible that there may be
differences in sample quality, as some blood spot sam-
ples were stored for more than 30 years, although there
was no difference in the number of samples that failed
quality control between the cord blood and blood spot
datasets. The correlation between DNAm GA and clinic-
ally estimated GA was 0.94 (median error (m.e.) = 1.4)
for samples processed on the HumanMethylation450
array and 0.55 (m.e. = 1.02) for samples processed on the
HumanMethylation27 array (Additional file 1: Figure S8).
This discrepancy is likely due to the differences in GA
range between samples run on the two arrays (19.3 and
11.1 weeks, respectively). Finally, the partial correlation
from regressions of DNAm GA on clinically estimated GA
did not substantially change when cell composition
covariates were included, suggesting that the accuracy of
the predictor is not confounded by cellular heterogeneity
(roriginal = 0.91, rcell type adjusted = 0.81).
To limit concerns regarding the potential for overfitting
of the models, we next validated the predictor in a second
testing dataset, comprised of 92 samples from three cohorts
(FAP, GSE66459, and GSE69633) that were not included in
the initial testing or training sets. Cohort demographics are
provided in Additional file 1: Table S3. The correlation in
these datasets is similar to that of the first testing
dataset (r = 0.89, m.e. = 0.89; Additional file 1: Figure S9),
further indicating that this model fits well when applied to
novel datasets and should be generalizable to other studies.
Accuracy of DNAm GA in the same subjects
Serial blood sampling was conducted from two neonates
admitted to the Neonatal Intensive Care Unit (NICU),
independent of the testing and training samples. Seven
timepoints were collected between birth at 25 weeks and
discharge at 40 weeks. DNAm GA increased as expected
over time from birth until term equivalency (Fig. 2). These
pilot data demonstrate that the predictor has the sensitivity
required to detect changes in DNAm GA in the magnitude
of days or weeks and that methylation patterns change
from birth to term equivalency in a predictable manner.
DNAm GA as a measure of developmental age
In adults, the difference between DNAm-based age esti-
mates and chronological age associates with all cause
mortality, HIV status, and Down syndrome [17, 42, 43].
This difference is usually described as age acceleration
[13]. We calculated a similar measure, which we will
subsequently refer to as “GA acceleration”, in our co-
horts by using the residual of a linear model regressing
Fig. 2 Reproducibility of DNAm GA. DNAm GA from birth until term
equivalency for two subjects recruited through the EpiPrem study,
gestational age at birth 25 weeks. DNAm GA increases appropriately
with gestational age in weeks. Change in DNAm GA over equivalent
weeks gestation
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DNAm GA on clinically estimated GA. Because acceler-
ated GA may indicate increased developmental maturity,
we sought to evaluate whether GA acceleration associ-
ated with perinatal measures of health and development
in the cohorts with available data.
Birthweight is widely used as a proxy of developmental
maturity in studies assessing the association between the
prenatal environment and short-term or long-term neo-
natal risk, with those born at the lowest birthweight gener-
ally having the highest risk for mortality over the first
year of life and for cardio-metabolic conditions as adults
[44, 45]. Birthweight is positively correlated with GA so
birthweight percentile, which is calculated based on birth-
weight averages for a given GA corrected for fetal sex, is
commonly used as an indicator of perinatal health [46, 47].
Previous studies have shown that infants in the lowest
birthweight percentiles have an increased risk of perinatal
death and other adverse outcomes and are often defined as
growth restricted [48, 49]. In cohorts with available data,
GA acceleration significantly predicted birthweight percent-
ile (p = 4.5 × 10−4; Fig. 3a) and birthweight (p = 0.033;
Fig. 3b) after correcting for clinically estimated GA, race,
estimated cell type proportions, and cohort. Consistent
with the idea that DNAm GA may reflect maturity, the fit-
ted regression model predicts approximately the 50th per-
centile to have GA acceleration of 0. Thus, neonates falling
in the lowest birthweight percentiles show lower, while
neonates falling in the highest percentiles show higher or
accelerated GA. There was no association between GA
acceleration calculated using the DNAm age predictor of
Horvath [13] and either birthweight or birthweight
percentile (Additional file 1: Figure S10).
One study by Appleton and colleagues [50] suggests that
socioeconomic adversity promotes adverse health outcomes
through epigenetic programming of neonatal DNAm. We
hypothesize that factors related to early life adversity might
influence the developmental age of the neonate. One such
factor is socioeconomic status, which is essential to exam-
ine as children born into socioeconomically disadvantaged
families, often operationalized by insurance status (Medic-
aid versus private health insurance), have poorer health in
childhood and early adulthood [51, 52]. In the most socio-
economically diverse cohort (CANDLE), GA acceleration
associated with maternal Medicaid status (p = 0.023) after
adjusting for race, clinically estimated GA, and estimated
cell type proportions (Fig. 4). Specifically, methylation-
based estimates of GA were lower than clinical estimates
for the neonates of women on Medicaid compared with
women with private health insurance. This association
supports the hypothesis that prenatal adversity associ-
ates with changes in neonatal methylation consistent
with a delayed developmental age, which may have con-
sequences later in life.
Conclusions
GA can be accurately predicted between 24 and 44 weeks
gestation using DNAm values obtained from both umbilical
cord blood and blood spot samples. DNAm GA is more
concordant with GA estimates performed with the gold
standard of ultrasound than with estimates based on LMP.
However, the question remains as to whether GA acceler-
ation is truly a measure of maturity versus a reflection of
the relative accuracy of DNAm GA compared with clinical
estimates. We consider three possibilities for interpreting
the difference between DNAm GA and clinically estimated
GA. First, an accelerated GA may reflect differences in
physiological development of the neonate such that neo-
nates with a higher DNAm GA are more developmentally
mature than their chronological age suggests. A second
possibility is that the differences between DNAm GA and
chronological GA reflect epigenetic programming by early
life environmental exposures, such as maternal prenatal
stress or pregnancy disorders, which may affect neonatal
outcomes and development [53]. Finally, any difference
a b
Fig. 3 GA acceleration associates with birthweight. The association between GA acceleration and a birthweight percentile (p= 4.5 × 10−4) or b birthweight
(p = 0.033) adjusted for race, cellular composition, cohort, and gestational age in CANDLE, WMHP, and PROGRESS. Solid line= regression line
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may simply be reflective of the variable nature of clinical
GA estimations; evaluation of DNAm GA in neonates con-
ceived through in vitro fertilization would be helpful for de-
lineating these different possibilities. These models may be
interrelated, such that the true interpretation is likely a
combination of these possibilities. A future study examining
other prediction methods, including the use of non-linear
models or transformations, may facilitate this interpretation
by further delineating developmental differences between
early and late GAs. Overall, our results suggest that DNAm
GA and GA acceleration are promising tools for evaluating
neonatal developmental maturity.
A targeted assay of the CpG sites necessary to compute
DNAm GA could provide a rapid and robust estimator of
GA at birth, and the framework described in this paper
could be used to develop and validate a predictor based on
other tissues that may be sampled prior to delivery, such as
chorionic villi or amniotic fluid. Our results suggest that
DNAm GA is highly reproducible and can predict measures
of developmental maturity, such as birthweight, better than
clinical estimates of GA alone. As such, it has the potential
to serve as a biomarker for GA and the rate of neonatal de-
velopment. Recent studies of GA and DNAm [23–26] sup-
port that shifts in methylation underlie the aging process,
further supporting the development of methylation-based
biomarkers. DNAm is a convenient molecular marker for
GA in that umbilical cord blood and blood sampling are
routinely performed to monitor neonatal health in humans,
and it can be readily sampled repeatedly in the same
person, as demonstrated by the time course data in the
subjects from preterm birth through term equivalency.
As a biomarker, DNAm GA and GA acceleration would
have numerous clinical, research, and forensic applications.
It would serve as a molecular marker of GA that comple-
ments clinical estimates, when available, and provides add-
itional information when clinical estimates are unavailable
or unreliable. For example, it could be used to estimate GA
in women who seek prenatal care late in pregnancy, are un-
sure of the date of their last menstrual period, or did not
have ultrasounds performed early in pregnancy. DNAm
GA is more precise than the estimation methods typically
performed at birth, which rely on biometric measurements.
Precise knowledge of GA would be most informative for
neonates born extremely preterm, when parents and
clinicians are confronted with decisions regarding active in-
tensive care interventions versus providing comfort care.
GA based on an epigenetic developmental profile may also
complement clinical estimates of GA, providing a screening
tool to identify children who may benefit from additional
monitoring and care. Studies to explore the extent to which
DNAm GA reflects developmental maturity, and thus may
be a more reliable predictor of outcomes after preterm birth
compared to time or growth-based methods, are needed.
DNAm GA may also serve as a surrogate marker for de-
velopmental maturity in research studies of neonatal de-
velopment, interventions, and disease. Our results already
demonstrate that it will be fruitful to study antenatal and
perinatal factors that associate with DNAm GA and GA
acceleration and to determine whether these metrics are
better prognosticators of neonatal well-being than con-
ventional measures. Future studies should evaluate the ef-
fects of maternal stress, nutrition, and interventions such
as vitamin supplementation that are highly relevant to
fetal development and pregnancy outcomes. Future re-
search could also explore whether GA acceleration relates
to risk of developing pediatric disorders, such as autism,
and whether it can predict health outcomes later in life.
Finally, establishing precise GA is important for forensic,
anthropologic, or other medico-legal investigations. In-
deed, DNAm-based predictors of adult age are already
under investigation for forensic applications [54]. In sum-
mary, we have identified a potential biomarker for GA
with an abundance of applications that warrant further in-
vestigation and development.
Methods
Description of cohorts
Training datasets were selected to include a wide range of
GAs and ancestries. Publically available datasets were
downloaded from the Gene Expression Omnibus (GEO):
GSE36642, GSE62924 [27], GSE51180 [55], and GSE30870
[56]. Methylation data for all of these datasets were gener-
ated on either the Illumina Infinium HumanMethylation27
BeadChip or Infinium HumanMethylation450 BeadChip
(Table 1). These methods have been shown to be highly
reproducible and consistent with the results of other
epigenetic methods [57, 58]. For umbilical cord blood
Fig. 4 Maternal insurance status and GA acceleration. Neonates
born to mothers with private insurance have higher GA acceleration
than neonates born to mothers on Medicaid (p = 0.023) after
adjusting for race, gestational age, and cellular composition
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samples, GA was defined as the GA at birth. For blood
spot samples, GA was defined as the GA plus the number
of days that occurred between birth and sampling. The
individual cohorts are detailed in Additional file 1.
Quality control and normalization
All analyses were performed using R version 3.1.2.
Datasets used in this study underwent several quality
control measures. The DNAm age predictor developed
by Horvath was initially run on all samples to establish
predicted age and gender [13]. Samples with gender dis-
cordance or estimated age >1.5 years were excluded from
further analysis. After this initial quality control step, data-
sets were subjected to standard quality control through
the use of the R package CpGassoc [59]. A data frame
consisting of β values (Methylated signal/(Methylated
signal + Unmethylated signal)) was supplied as input to
CpGassoc. Any data point with a detection p value above
0.001 was set to missing. CpG sites with >5 % missing data
were excluded; subsequently, samples with >5 % missing
data were excluded. These quality control measures were
performed to ensure that the predictor is built based on
high quality probes and samples. Any probe missing en-
tirely from one of the datasets was excluded from the
remaining datasets, so only probes passing quality control
in all training datasets and probes present on both the
HumanMethylation450 and HumanMethylation27 arrays
were included, for a total of 16,838 probes. Finally, data-
sets were normalized according to Horvath’s modified
beta-mixture quantile (BMIQ) normalization [13, 60].
While the original BMIQ is a within-sample normalization
method to address probe type bias by modifying the type
II distribution to match that of type I probes, Horvath
modified this BMIQ procedure for a different purpose: the
distribution of each given array is related to that of a “gold
standard” array (defined here as the mean across all of the
training datasets). Thus, Horvath’s modification of the
BMIQ method could be interpreted as a form of between-
sample normalization. All training datasets were normal-
ized together, as a single group. After normalization,
missing values for each sample were imputed by the
k-nearest neighbors method where k = 10, using the R
package impute so that no missing values remain in the
dataset after pipeline completion [61]. Test datasets were
normalized separately, following the same procedures as
above. One test cohort, PROGRESS, which was processed
with an out of band background correction, dye bias cor-
rection, and then the original BMIQ procedure, was ex-
cluded from the quality control pipeline as raw files were
not available. Principal components analysis was used to
assess the potential impact of BeadChip on the CpG sites
selected for inclusion in the predictor. We did not observe
clustering by chip (Additional file 1: Figure S11), suggest-
ing that the chip was not a confounding factor.
Estimation of cellular composition
Proportions of white blood cells and nucleated red blood
cells were estimated from genome-wide DNAm patterns
using the method proposed by Houseman et al. [62],
with reference samples from homogenous cell popula-
tions for white blood cells (CD4+ T cells, CD8+ T cells,
natural killer cells, B cells, monocytes, and granulocytes),
nucleated red blood cells [63, 64], and whole blood
(GSE80310).
Epigenome-wide association study
The R package CpGassoc [59] was used to perform
epigenome-wide association studies (EWAS) to assess
associations between GA and DNAm. Two separate
EWAS were performed, with and without the inclusion
of cellular composition covariates. Each EWAS was per-
formed as a meta-analysis across all cohorts by including
indicators for each study as covariates. Test statistics
from the two EWAS were plotted to assess the robust-
ness of results to potential cell type heterogeneity.
Elastic net regression and age prediction
The six training datasets (GSE36642, WMHP1, GSE62924,
NBC, GSE51180, and GSE30870) were combined to per-
form an elastic net regression of GA on the 16,838 CpG
probes remaining after quality control and filtering. The
regression was performed using the R package glmnet to
select a parsimonious set of CpG sites predictive of GA.
Following Horvath [13], the elastic net mixing parameter,
alpha, was set to 0.5 allowing for equal contribution of the
ridge and lasso methods [65]. The lambda parameter was
chosen through a tenfold cross validation, which involves
randomly partitioning the training dataset into ten equally
sized subsamples. The cross-validation procedure is then
performed ten times, retaining a different subsample as a
validation dataset each time. In the procedure, data from
the other nine subsamples are used to build a predictor
based on a particular value of lambda, and the fit of the
predictor is then tested in the omitted validation set. The
mean squared error is calculated for the validation set in
each iteration and then averaged over the ten subsamples.
This procedure is performed for a sequence of lambda
values to determine the lambda that yields the minimum
mean squared error. No additional covariates were in-
cluded in the analysis, consistent with the development of
the DNAm age predictor by Horvath [13]. The training co-
efficient values and CpG probes selected from this regres-
sion were used to fit a linear model to generate predicted
values of GA, based on a modified version of the R code in
the DNAm age tutorial published by Horvath [13]. The
accuracy of predicted values of GA was determined from
correlation coefficients obtained through linear regression
of DNAm GA and clinical GA.
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Analysis of GA acceleration
GA acceleration was calculated as the residual from a linear
regression of DNAm GA on clinical estimates of GA for
the combined testing dataset. Analysis of DNAm GA with
birthweight and birthweight percentile was then conducted
using linear regression of birthweight and birthweight
percentile on GA acceleration and covariates for race,
estimated cell type proportions, and cohort. Clinically esti-
mated GA was included as a covariate in the analysis for
birthweight but not birthweight percentile as birthweight
percentile is already adjusted for clinically estimated GA.
Maternal insurance status (as a proxy for income) was ana-
lyzed in the CANDLE cohort through logistic regression of
maternal insurance status on GA acceleration, adjusting for
estimated clinical GA, race (African American versus
Caucasian), and estimated cell type proportions.
Enrichment tests
To assess whether the CpG sites selected for the DNAm
GA predictor were more likely than others to be located in
functionally relevant regions, two approaches were used.
First, CpG positions were intersected with the hg19 CpG
island annotation track from the UCSC Genome Browser
(http://genome.ucsc.edu) to define whether each site was
located in a CpG island, CpG shore (±1.5 kb from island),
or CpG shelf (±1.5 kb from shore). Second, the CpG posi-
tions were intersected with ENCODE’s ChromHMM an-
notation for lymphoblastoid cell line GM12878, which uses
a hidden Markov model to assign genomic features based
on the combinatorial pattern of various chromatin marks
[66]. The ChromHMM annotation allowed identification
of CpGs located in promoters and enhancers. Fisher’s exact
test was used to assess whether there was significant
enrichment of each feature in CpG sites selected for the
predictor compared to the full set of 16,838 sites included
in the elastic net model. A similar analysis was preformed
to assess whether these CpG sites were enriched for sites
containing a genetic variant in the 50-bp probe (using an-
notation derived from the 1000 Genomes Project) or sites
previously reported to associate with race [31]. DAVID was
used to evaluate whether CpG sites used to estimate
DNAm GA were located in genes enriched for any bio-
logical pathways [32].
Additional files
Additional file 1: Figures S1–S11 and Tables S1–S3. (PDF 3090 kb)
Additional file 2: CpG sites and corresponding genes used to predict
DNAm age. (XLSX 43 kb)
Additional file 3: CpG sites and coefficients used to predict DNAm age.
(CSV 3 kb)
Additional file 4: Wrapper program for predicting gestational age. (R 6 kb)
Additional file 5: R code to normalized and predict DNAm age. (R 6 kb)
Additional file 6: Test dataset for predicting DNAm age. (CSV 1240 kb)
Additional file 7: Instructions for predicting gestational age from cord
blood and blood spot methylation. (DOCX 137 kb)
Additional file 8: Relevant data from PROGRESS cohort. (CSV 282 kb)
Acknowledgements
The authors gratefully acknowledge Dr. Isabel Iglesias Platas, Dr. Holger Heyn,
and Dr. Manel Esteller for providing their unpublished data for the training
dataset.
Funding
This research was supported by grants from the National Institutes of
Minority and Health Disparities (R01MD009064 to AKS), the National Health
and Medical Research Council of Australia (project grants 1083779, 491246;
Centre of Research Excellence Grants 546519, 1060733, early career
fellowship to JLYC 1053787), and the Urban Child Institute. Salary support for
AKK, EMK, and SEP was provided, in part, by the National Institute of General
Medical Sciences (T32GM008490) and the National Institute of Environmental
Health Sciences (T32ES012870), respectively. Salary support for ACJ was
provided by NIEHS grant K99 ES023450. Salary support for SH was provided
by NIH/NIA 1U34AG051425-01. Support for PREDO was provided by the
Academy of Finland (grants 127437, 129306, 130326, 134791, and 263924),
Sigrid Juselius Foundation, Foundation for Pediatric Research, Novo Nordisk
Foundation (to EK). Additional support provided by the Academy of Finland
grants 121196 and 134791, Finnish Medical Society Duodecim, Government
Special Subsidy for Health Sciences at Helsinki and Uusimaa Hospital District,
Jane and Aatos Erkko Foundation, Päivikki and Sakari Sohlberg Foundation,
and University of Helsinki Research Funds (to HL). The PROGRESS/ELEMENT
study was supported by funding from the National Institute of Environmental
Health Sciences (R01ES020268; R01ES021357) and by the National Institute of
Public Health/Ministry of Health of Mexico. The American British Cowdray
Hospital provided facilities used for PROGRESS/ELEMENT research. WMHP
sample collection was supported by the Translational Research Center in
Behavioral Sciences (TRCBS; P50 MH077928 to ZNS) and methylation assays
were provided by the National Institute of Mental Health (RC1 MH088609
to AKS/PAB). The FAP study was supported by the Georgia Experimental
Agriculture Station, HATCH #GEO00706 and the Interdisciplinary Proposal
Developmental Program at the University of Georgia.
Availability of data and materials
R code and documentation for predicting DNAm GA is included as Additional
files 3, 4, 5, 6, and 7 and requires Additional files 21, 22, and 24 from Horvath [13]
or can be accessed at https://github.com/akknight/PredictGestationalAge under
an open-source, MIT license (DOI 10.5281/zenodo.60519). The datasets supporting
the conclusions of this article are available in NCBI Gene Expression Omnibus
(GEO) under accession numbers: GSE64940 (CANDLE, https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE64940), GSE79056 (NBC, https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE79056), GSE80283 (VICS, https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE80283), GSE79969 (EpiPrem, https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79969), GSE80310 (FAP,
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80310), GSE36642
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36642), GSE62924
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62924), GSE51180
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51180), GSE30870
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30870), GSE66459
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse66459) GSE69633
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse69633), the European
Genome Phenome Archive under accession number EGAS00001001898 (PREDO,
https://www.ebi.ac.uk/ega/studies/EGAS00001001898). Relevant data from
PROGRESS are provided as Additional file 8. Subject enrollment and ascertainment
for the WMHP cohorts was obtained under NIH grant P50 MH-77928, which
established a Data Enclave through which investigators can request clinical and
molecular data from the center director (ZNS). This approach was approved by
NIH due to 1) the sensitive privacy issues specific to clinical research data, 2) the
vulnerable population to be studied, and 3) the inclusion of medical information
such as obstetrical and labor and delivery records that makes complete
de-identification difficult to achieve. Individual level data for DNSBtrios is not
publically availably due to legal restrictions in the country where it was collected.
Knight et al. Genome Biology  (2016) 17:206 Page 8 of 11
Authors’ contributions
AKK carried out the data analysis to develop and test the predictor of
gestational age and drafted the manuscript. JMC and PD participated in
methylation analysis of VICS. LWD and JLYC contributed to data collection
(VICS). YJL optimized the DNA extraction of dried blood in VICS and was
involved in manuscript revisions. CT participated in the planning and analysis
(VICS) and provided methylation data as PI of the EpiPrem study. PMV, EK,
KR, HL, EBB, SI, AKP, DC, EH, and JMTL participated in the design and
execution of the PREDO study. PBM, SMW, and TMW initiated the DNSBtrios
study. PBM identified the samples. SMW and TMW quality controlled the
data. MBH, JBG, CSH, MVH, and DH prepared the DNSBtrios, extracted the
DNA, processed the methylation arrays, quality controlled the cohort and
prepared the data for inclusion in the study. ZNS and DJN initiated sample
collection in WMHP. PAB, JFC, and AKS initiated studies of DNAm and
contributed to generation and analysis of the methylation data from WHMP.
SEP and RM participated in the execution of the NBC study. MMTR contributed
to the design and acquisition of the PROGRESS cohort. KS cleaned the
phenotypic data and oversaw the process of the PROGRESS database
management. ACJ oversaw the quality control and preprocessing analysis of
the PROGRESS methylation data. LT generated the plating scheme for
PROGRESS samples and assisted in quality control. ROW designed the
PROGRESS study as PI and oversaw collection of the cord blood samples.
AAB oversaw the methylation analysis and methylation study design. NRB, KZL,
and FAT participated in the design and execution of the CANDLE study. HJP
and LBB initiated collection of the FAP cohort and participated in generation of
the methylation data. VK assisted in quality control and analysis of the WMHP,
NBC, and FAP cohorts. SH participated in the study design, validation of the
predictor, and data interpretation. KNC and AKS conceived of the study,
supervised the data analysis and interpretation, and made substantial revisions
to the manuscript. All authors participated in interpretation of the data and
manuscript revision. All authors read and approved the final manuscript.
Competing interests
The authors do not have any competing interests related to this work.
Ethics approval and consent to participate
This study was conducted in compliance with the Helsinki Declaration.
All subjects have given written informed consent, except participants of
DNSBtrios. Permission to include the Danish samples and phenotypes in the
study without individual informed consent from participants was granted
by the Danish Health Board according to the Law on Patient’s rights
(law number 482 of July 1st, 1998) on the condition that individual level
data not be made public and that no attempt to identify or contact participants
be made. The CANDLE study was approved by the Institutional Review Board of
the University of Tennessee Health Science Center (06-08495-FB). The EpiPrem
and VICS studies were approved by the Human Research Ethics Committee at
the Royal Women’s Hospital Melbourne (projects 13/43 and 08/06). The FAP
study was approved by the University of Georgia Institutional Review Board on
Human Subjects (STUDY0000050) and the Athens Regional Medical Center
Institutional Review Board. The study was registered at ClinicalTrials.gov
(NCT02124642). The NBC study was approved by the Western Institutional
Review Board (PRC-1-2007). The PREDO study was approved by the Ethics
Committee of Obstetrics and Gynecology at Hospital District of Helsinki and
Uusimaa. The PROGESS study was approved by Mount Sinai Health System
Program for the Protection of Human Subjects; HS# 12-00751. The WMHP
studies were approved by the Emory University Institutional Review
Board (IRB00004249).
Author details
1Genetics and Molecular Biology Program, Emory University, Atlanta, GA,
USA. 2Murdoch Childrens Research Institute and Department of Paediatrics,
University of Melbourne, Parkville, Victoria 3052, Australia. 3The Royal
Women’s Hospital, Murdoch Childrens Research Institute and University of
Melbourne, Parkville, Victoria 3052, Australia. 4Section of Neonatal Genetics,
Danish Centre for Neonatal Screening, Department for Congenital Disorders,
Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. 5The
Danish Neonatal Screening Biobank, Department for Congenital Disorders,
Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
6National Centre for Register-based Research, School of Business and Social
Sciences, Aarhus University, Fuglesangs Allé 4, 8210 Aarhus V, Denmark.
7Institute of Biological Psychiatry, Sct. Hans Mental Health Center,
Copenhagen Mental Health Services, iPSYCH - The Lundbeck Foundation’s
Initiative for Integrative Psychiatric Research, Boserupvej, DK-4000 Roskilde,
Denmark. 8Department of Psychology, Emory University, Atlanta, GA, USA.
9Department of Human Genetics, Emory University School of Medicine,
Atlanta, GA, USA. 10Department of Psychiatry & Behavioral Sciences, Emory
University School of Medicine, Atlanta, GA, USA. 11Departments of Psychiatry
& Behavioral Sciences and Obstetrics & Gynecology, University of Miami
Miller School of Medicine, Miami, FL, USA. 12Departments of Psychiatry &
Behavioral Sciences, Pediatrics, and Obstetrics & Gynecology, University of
Arkansas for Medical Sciences, Little Rock, AR, USA. 13Laboratory of
Environmental Precision Biosciences, Columbia University Mailman School of
Public Health, New York, NY, USA. 14Department of Preventive Medicine,
Icahn School of Medicine at Mount Sinai, New York, NY, USA. 15Center for
Nutrition and Health Research, National Institute of Public Health,
Cuernavaca, Morelos, Mexico. 16Department of Environmental Health,
Harvard T.H. Chan School of Public Health, Boston, MA, USA. 17Department
of Translational Research in Psychiatry, Max-Planck Institute of Psychiatry,
Munich, Germany. 18Institute of Behavioral Sciences, University of Helsinki,
00014 Helsinki, Finland. 19Helsinki Collegium for Advanced Studies, University
of Helsinki, Helsinki, Finland. 20Folkhälsan Research Centre, Helsinki, Finland.
21National Institute for Health and Welfare, Children’s Hospital, Helsinki
University Hospital, 00271 Helsinki, Finland. 22University of Helsinki, 00029
Helsinki, Finland. 23Department of Obstetrics and Gynecology, MRC Oulu,
Oulu University Hospital and University of Oulu, Oulu, Finland. 24Obstetrics
and Gynaecology, University of Helsinki and Helsinki University Hospital,
00014 Helsinki, Finland. 25Medical and Clinical Genetics, and Obstetrics and
Gynecology, University of Helsinki and Helsinki University Hospital, 00014
Helsinki, Finland. 26Institute for Molecular Medicine Finland, University of
Helsinki, 00014 Helsinki, Finland. 27HUSLAB and Department of Clinical
Chemistry, Helsinki University Central Hospital, 00014 Helsinki, Finland.
28Department of Gynecology and Obstetrics, Emory University School of
Medicine, Atlanta, GA, US. 29Department of Obstetrics and Gynecology,
University of Texas Medical Branch, Galveston, TX, US. 30Department of
Human Genetics, David Geffen School of Medicine University of California
Los Angeles, Los Angeles, CA 90095, US. 31Department of Biostatistics,
Fielding School of Public Health, University of California Los Angeles, Los
Angeles, CA 90095, US. 32Department of Psychiatry, University of California,
San Francisco, CA, US. 33Department of Pediatrics, University of California, San
Francisco, CA, US. 34Department of Preventive Medicine, University of
Tennessee Health Science Center, Memphis, TN, US.
Received: 19 April 2016 Accepted: 20 September 2016
References
1. Young PC, Glasgow TS, Li X, Guest-Warnick G, Stoddard G. Mortality of
late-preterm (near-term) newborns in Utah. Pediatrics. 2007;119:e659–665.
2. Engle WA. Morbidity and mortality in late preterm and early term
newborns: a continuum. Clin Perinatol. 2011;38:493–516.
3. Yang S, Platt RW, Kramer MS. Variation in child cognitive ability by week of
gestation among healthy term births. Am J Epidemiol. 2010;171:399–406.
4. Davis EP, Buss C, Muftuler LT, Head K, Hasso A, Wing DA, Hobel C, Sandman CA.
Children’s brain development benefits from longer gestation. Front Psychol.
2011;2:1.
5. Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory
morbidity in term infants delivered by elective caesarean section: cohort
study. BMJ. 2008;336:85–7.
6. Parikh LI, Reddy UM, Mannisto T, Mendola P, Sjaarda L, Hinkle S, Chen Z,
Lu Z, Laughon SK. Neonatal outcomes in early term birth. Am J Obstet
Gynecol. 2014;211:265. e1–265.e11.
7. ACOG. Committee Opinion No 579: Definition of term pregnancy. Obstet
Gynecol. 2013;122:1139–40.
8. Extremely Preterm Birth. http://www.acog.org/Patients/FAQs/Extremely-
Preterm-Birth.
9. Lynch CD, Zhang J. The research implications of the selection of a gestational
age estimation method. Paediatr Perinat Epidemiol. 2007;21 Suppl 2:86–96.
10. Mongelli M, Wilcox M, Gardosi J. Estimating the date of confinement:
ultrasonographic biometry versus certain menstrual dates. Am J Obstet
Gynecol. 1996;174:278–81.
11. Dubowitz LM, Dubowitz V, Goldberg C. Clinical assessment of gestational
age in the newborn infant. J Pediatr. 1970;77:1–10.
Knight et al. Genome Biology  (2016) 17:206 Page 9 of 11
12. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New
Ballard Score, expanded to include extremely premature infants. J Pediatr.
1991;119:417–23.
13. Horvath S. DNA methylation age of human tissues and cell types. Genome
Biol. 2013;14:R115.
14. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B,
Bibikova M, Fan JB, Gao Y, et al. Genome-wide methylation profiles reveal
quantitative views of human aging rates. Mol Cell. 2013;49:359–67.
15. Bocklandt S, Lin W, Sehl ME, Sanchez FJ, Sinsheimer JS, Horvath S, Vilain E.
Epigenetic predictor of age. PLoS One. 2011;6:e14821.
16. Weidner CI, Lin Q, Koch CM, Eisele L, Beier F, Ziegler P, Bauerschlag DO,
Jockel KH, Erbel R, Muhleisen TW, et al. Aging of blood can be tracked by
DNA methylation changes at just three CpG sites. Genome Biol. 2014;15:R24.
17. Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, Gibson J,
Henders AK, Redmond P, Cox SR, et al. DNA methylation age of blood
predicts all-cause mortality in later life. Genome Biol. 2015;16:25.
18. Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, Christensen K.
DNA methylation age is associated with mortality in a longitudinal Danish
twin study. Aging Cell. 2016;15:149–54.
19. Horvath S, Pirazzini C, Bacalini MG, Gentilini D, Di Blasio AM, Delledonne M,
Mari D, Arosio B, Monti D, Passarino G, et al. Decreased epigenetic age of
PBMCs from Italian semi-supercentenarians and their offspring. Aging
(Albany NY). 2015;7:1159–70.
20. Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, Gibson J,
Redmond P, Cox SR, Pattie A, et al. The epigenetic clock is correlated with
physical and cognitive fitness in the Lothian Birth Cohort 1936. Int J Epidemiol.
2015;44:1388–96.
21. Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal
cortex is associated with neuritic plaques, amyloid load, and Alzheimer’s
disease related cognitive functioning. Aging (Albany NY). 2015;7:1198–211.
22. Breitling LP, Saum KU, Perna L, Schottker B, Holleczek B, Brenner H. Frailty is
associated with the epigenetic clock but not with telomere length in a
German cohort. Clin Epigenetics. 2016;8:21.
23. Parets SE, Conneely KN, Kilaru V, Fortunato SJ, Syed TA, Saade G, Smith AK,
Menon R. Fetal DNA methylation associates with early spontaneous preterm
birth and gestational age. PLoS One. 2013;8:e67489.
24. Schroeder JW, Conneely KN, Cubells JC, Kilaru V, Newport DJ, Knight BT, Stowe
ZN, Brennan PA, Krushkal J, Tylavsky FA, et al. Neonatal DNA methylation
patterns associate with gestational age. Epigenetics. 2011;6:1498–504.
25. Simpkin AJ, Suderman M, Gaunt TR, Lyttleton O, McArdle WL, Ring SM,
Tilling K, Davey Smith G, Relton CL. Longitudinal analysis of DNA
methylation associated with birth weight and gestational age. Hum Mol
Genet. 2015;24(13):3752-63.
26. Lee H, Jaffe AE, Feinberg JI, Tryggvadottir R, Brown S, Montano C, Aryee MJ,
Irizarry RA, Herbstman J, Witter FR, et al. DNA methylation shows genome-wide
association of NFIX, RAPGEF2 and MSRB3 with gestational age at birth.
Int J Epidemiol. 2012;41:188–99.
27. Rojas D, Rager JE, Smeester L, Bailey KA, Drobna Z, Rubio-Andrade M, Styblo M,
Garcia-Vargas G, Fry RC. Prenatal arsenic exposure and the epigenome:
identifying sites of 5-methylcytosine alterations that predict functional changes
in gene expression in newborn cord blood and subsequent birth outcomes.
Toxicol Sci. 2015;143:97–106.
28. Smith AK, Conneely KN, Newport DJ, Kilaru V, Schroeder JW, Pennell PB,
Knight BT, Cubells JC, Stowe ZN, Brennan PA. Prenatal antiepileptic
exposure associates with neonatal DNA methylation differences.
Epigenetics. 2012;7:458–63.
29. Schroeder JW, Smith AK, Brennan PA, Conneely KN, Kilaru V, Knight BT,
Newport DJ, Cubells JF, Stowe ZN. DNA methylation in neonates born to
women receiving psychiatric care. Epigenetics. 2012;7:409–14.
30. Nemoda Z, Massart R, Suderman M, Hallett M, Li T, Coote M, Cody N, Sun ZS,
Soares CN, Turecki G, et al. Maternal depression is associated with DNA
methylation changes in cord blood T lymphocytes and adult hippocampi.
Transl Psychiatry. 2015;5:e545.
31. Adkins RM, Krushkal J, Tylavsky FA, Thomas F. Racial differences in gene-specific
DNA methylation levels are present at birth. Birth Defects Res A Clin Mol Teratol.
2011;91:728–36.
32. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
33. Barfield RT, Almli LM, Kilaru V, Smith AK, Mercer KB, Duncan R, Klengel T,
Mehta D, Binder EB, Epstein MP, et al. Accounting for population
stratification in DNA methylation studies. Genet Epidemiol. 2014;38:231–41.
34. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O’Donovan MC,
Bray NJ, Mill J. Methylomic trajectories across human fetal brain
development. Genome Res. 2015;25:338–52.
35. Simpkin AJ, Hemani G, Suderman M, Gaunt TR, Lyttleton O, McArdle WL,
Ring SM, Sharp GC, Tilling K, Horvath S, et al. Prenatal and early life
influences on epigenetic age in children: A study of mother-offspring pairs
from two cohort studies. Hum Mol Genet. 2015;25(1):191-201.
36. Nguyen TH, Larsen T, Engholm G, Moller H. Evaluation of ultrasound-estimated
date of delivery in 17,450 spontaneous singleton births: do we need to modify
Naegele’s rule? Ultrasound Obstet Gynecol. 1999;14:23–8.
37. Moore KA, Simpson JA, Thomas KH, Rijken MJ, White LJ, Dwell SL, Paw MK,
Wiladphaingern J, Pukrittayakamee S, Nosten F, et al. Estimating gestational
age in late presenters to antenatal care in a resource-limited setting on the
Thai-Myanmar border. PLoS One. 2015;10:e0131025.
38. Donovan EF, Tyson JE, Ehrenkranz RA, Verter J, Wright LL, Korones SB,
Bauer CR, Shankaran S, Stoll BJ, Fanaroff AA, et al. Inaccuracy of Ballard scores
before 28 weeks’ gestation. National Institute of Child Health and Human
Development Neonatal Research Network. J Pediatr. 1999;135:147–52.
39. Sanders M, Allen M, Alexander GR, Yankowitz J, Graeber J, Johnson TR,
Repka MX. Gestational age assessment in preterm neonates weighing less
than 1500 grams. Pediatrics. 1991;88:542–6.
40. Karunasekera KA, Sirisena J, Jayasinghe JA, Perera GU. How accurate is the
postnatal estimation of gestational age? J Trop Pediatr. 2002;48:270–2.
41. Dubowitz L, Ricciw D, Mercuri E. The Dubowitz neurological examination of
the full-term newborn. Ment Retard Dev Disabil Res Rev. 2005;11:52–60.
42. Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D,
Di Blasio AM, Giuliani C, Tung S, Vinters HV, Franceschi C. Accelerated
epigenetic aging in Down syndrome. Aging Cell. 2015;13(3):491-95.
43. Horvath S, Levine AJ. HIV-1 infection accelerates age according to the
epigenetic clock. J Infect Dis. 2015;212:1563–73.
44. Wilcox AJ, Russell IT. Birthweight and perinatal mortality: II. On weight-specific
mortality. Int J Epidemiol. 1983;12:319–25.
45. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr.
2000;71:1344S–52S.
46. Coory M. Does gestational age in combination with birthweight provide
better statistical adjustment of neonatal mortality rates than birthweight
alone? Paediatr Perinat Epidemiol. 1997;11:385–91.
47. Hertz-Picciotto I, Din-Dzietham R. Comparisons of infant mortality using a
percentile-based method of standardization for birthweight or gestational
age. Epidemiology. 1998;9:61–7.
48. Boulet SL, Alexander GR, Salihu HM, Kirby RS, Carlo WA. Fetal growth risk
curves: defining levels of fetal growth restriction by neonatal death risk.
Am J Obstet Gynecol. 2006;195:1571–7.
49. Patterson RM, Prihoda TJ, Gibbs CE, Wood RC. Analysis of birth weight
percentile as a predictor of perinatal outcome. Obstet Gynecol.
1986;68:459–63.
50. Appleton AA, Armstrong DA, Lesseur C, Lee J, Padbury JF, Lester BM, Marsit CJ.
Patterning in placental 11-B hydroxysteroid dehydrogenase methylation
according to prenatal socioeconomic adversity. PLoS One. 2013;8:e74691.
51. Silva LM. Fetal origins of socioeconomic inequalities in early childhood
health. The Netherlands: The Generation R Study, Erasmus University
Rotterdam; 2009.
52. Kramer MS, Seguin L, Lydon J, Goulet L. Socio-economic disparities in
pregnancy outcome: why do the poor fare so poorly? Paediatr Perinat
Epidemiol. 2000;14:194–210.
53. Ching T, Ha J, Song MA, Tiirikainen M, Molnar J, Berry MJ, Towner D,
Garmire LX. Genome-scale hypomethylation in the cord blood DNAs
associated with early onset preeclampsia. Clin Epigenetics. 2015;7:21.
54. Yi SH, Xu LC, Mei K, Yang RZ, Huang DX. Isolation and identification of
age-related DNA methylation markers for forensic age-prediction.
Forensic Sci Int Genet. 2014;11:117–25.
55. Cruickshank MN, Oshlack A, Theda C, Davis PG, Martino D, Sheehan P, Dai Y,
Saffery R, Doyle LW, Craig JM. Analysis of epigenetic changes in survivors of
preterm birth reveals the effect of gestational age and evidence for a long
term legacy. Genome Med. 2013;5:96.
56. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A, Diez J, Sanchez-Mut JV,
Setien F, Carmona FJ, et al. Distinct DNA methylomes of newborns and
centenarians. Proc Natl Acad Sci U S A. 2012;109:10522–7.
57. Roessler J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar SL, Kreipe H,
Lehmann U. Quantitative cross-validation and content analysis of the 450k
DNA methylation array from Illumina, Inc. BMC Res Notes. 2012;5:210.
Knight et al. Genome Biology  (2016) 17:206 Page 10 of 11
58. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson
KL. Genome-wide DNA methylation profiling using Infinium((R)) assay.
Epigenomics. 2009;1:177–200.
59. Barfield RT, Kilaru V, Smith AK, Conneely KN. CpGassoc: an R function for
analysis of DNA methylation microarray data. Bioinformatics. 2012;28:1280–1.
60. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D,
Beck S. A beta-mixture quantile normalization method for correcting probe
design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics.
2013;29:189–96.
61. Hastie T, Tibshirani R, Balasubramanian N, Chu G. impute: Imputation for
microarray data. R package version 1.42.0. https://bioconductor.org/
packages/release/bioc/html/impute.html.
62. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ,
Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate
measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.
63. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D,
Soderhall C, Scheynius A, Kere J. Differential DNA methylation in purified
human blood cells: implications for cell lineage and studies on disease
susceptibility. PLoS One. 2012;7:e41361.
64. de Goede OM, Razzaghian HR, Price EM, Jones MJ, Kobor MS, Robinson WP,
Lavoie PM. Nucleated red blood cells impact DNA methylation and
expression analyses of cord blood hematopoietic cells. Clin Epigenetics.
2015;7:95.
65. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear
models via coordinate descent. J Stat Softw. 2010;33:1–22.
66. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X,
Wang L, Issner R, Coyne M, et al. Mapping and analysis of chromatin state
dynamics in nine human cell types. Nature. 2011;473:43–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Knight et al. Genome Biology  (2016) 17:206 Page 11 of 11
